Opaxio paclitaxel poliglumex: Preliminary Phase II data

Preliminary data from an open-label Phase II trial in 22 evaluable patients with newly-diagnosed high-grade glioma show that once-weekly 50 mg/m 2 Opaxio plus standard of care (SOC) for 6 weeks produc...